Clinical Analysis of Uncommon Epidermal Growth Factor Receptor Mutations in 16 Cases of Nonsmall Cell Lung Cancer

Abstract

All patients were diagnosed as NSCLC by pathological and immunohistochemistry examinations. [...]all the patients were at IIIb/IV stage or in advanced stages with postoperative recurrence. The median OS of the 13 cases was 35 months; however, median OS of the other 3 cases was 8.8 months. [...]this study believed that the prolonged OS was impacted largely by chemoradiotherapy, because it can clear some clones that were resistant to EGFR-TKIs and directly kill the tumor cells. In summary, PFS of the uncommon mutations in this study mostly were lower than the classical mutations, but higher than the EGFR wild types. [...]patients obtained survival benefits from the targeted therapy, and the longest PFS was up to 26 months.